BIIB-091

N/A

Report date: 2026/02/18 20:02:09
NME

Base Information

Drug NameBIIB-091
Drug Alias NameBIIB-091
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Inc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsMultiple Sclerosis, Relapsing-Remitting

Other Information

ATC CodeN/A
Related LinksN/A